This Article Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by ALFORD, F. P. Articles by NABARRo, J. D. N. Search for Related Content PubMed PubMed Citation Articles by ALFORD, F. P. Articles by NABARRo, J. D. N.

Glucagon Metabolism in Man. Studies on the Metabolic Clearance Rate and the Plasma Acute Disappearance Time of Glucagon in Normal and Diabetic Subjects

FRANK P. ALFORD^*, S. R. BLOOM and J. D. N. NABARRo

Cobbold Laboratories, Middlesex Hospital Medical School London, W.I, England

To investigate further the "hyperglucagonaemia" of diabetes mellitus, the metabolic clearance rate (MCR) and acute disappearance time (t) of unlabelled pancreatic glucagon were estimated in 9 normal subjects and 7 insulin-dependent diabetics, using a constant infusion technique. The mean MCR (±SE) was similar for both groups (control: 9.0 ± 0.6; diabetics: 11.4 ± 1.0 ml/kg/min). The MCR was not influenced by the concentration of glucagon at the time of plateau, and the exogenous hormone appeared to be handled similarly to endogenous glucagon. On the other hand, t calculated from the fractional decay rate of glucagon from plateau was significantly prolonged in the diabetics (t 6.6 ± 0.5 min) compared with the control g.oup (t 4.8 ± 0.2 min, P < 0.01). Furthermore, there was no correlation between MCR and t, for the control, diabetic, or combined group.

It therefore appears that the MCR of glucagon is similar in normal and diabetic subjects. However, since the acute disappearance time (t) of glucagon is not identical in these two groups, it appears that the kinetics of the overall in vivo metabolism of pancreatic glucagon are not similar in diabetic and control subjects.

Presented in part at the 140th Meeting of the British Society for Endocrinology, November, 1974, and the 9th Meeting of the European Society for Clinical Investigation, April, 1975.

^* Present address: Endocrine Unit, St. Vincent's Hospital, Victoria Parade, Fitzroy, 3065, Victoria, Australia.

Present address: Royal Postgraduate Medical School, Hammersmith Hospital, London, W.12.

Received June 16, 1975.

This article has been cited by other articles:

				S. A. Hinke, J. A. Pospisilik, H.-U. Demuth, S. Mannhart, K. Kuhn-Wache, T. Hoffmann, E. Nishimura, R. A. Pederson, and C. H. S. McIntosh Dipeptidyl Peptidase IV (DPIV/CD26) Degradation of Glucagon. CHARACTERIZATION OF GLUCAGON DEGRADATION PRODUCTS AND DPIV-RESISTANT ANALOGS J. Biol. Chem., February 11, 2000; 275(6): 3827 - 3834. [Abstract] [Full Text] [PDF]